Metastatic Breast Cancer in Kenya: Presentation, Pathologic Characteristics, and Patterns-Findings From a Tertiary Cancer Center by Ekpe, Etoroabasi et al.
eCommons@AKU
Internal Medicine, East Africa Medical College, East Africa
July 2019
Metastatic Breast Cancer in Kenya: Presentation,
Pathologic Characteristics, and Patterns-Findings
From a Tertiary Cancer Center
Etoroabasi Ekpe
Columbia University
Asim Jamal
Aga Khan University, asim.jamal@aku.edu
Jasmit Shah
Aga Khan University, jasmit.shah@aku.edu
Judith S. Jacobson
Columbia University
Shahin Sayed
Aga Khan University, shahin.sayed@aku.edu
Follow this and additional works at: https://ecommons.aku.edu/eastafrica_fhs_mc_intern_med
Part of the Internal Medicine Commons, Oncology Commons, and the Pathology Commons
Recommended Citation
Ekpe, E., Jamal, A., Shah, J., Jacobson, J. S., Sayed, S. (2019). Metastatic Breast Cancer in Kenya: Presentation, Pathologic
Characteristics, and Patterns-Findings From a Tertiary Cancer Center. Journal of Global Oncology, 5, 1-11.
Available at: https://ecommons.aku.edu/eastafrica_fhs_mc_intern_med/107
original
report
Metastatic Breast Cancer in Kenya:
Presentation, Pathologic Characteristics, and
Patterns—Findings From a Tertiary
Cancer Center
Etoroabasi Ekpe, MD, MPH1,2; Asim Jamal Shaikh, MBBS, FCPS3; Jasmit Shah, PhD3; Judith S. Jacobson, DrPH, MBA2; and
Shahin Sayed, MB ChB, MMED3
abstract
PURPOSE The purpose of this research was to describe the sociodemographic and clinical characteristics of
Kenyan women with metastatic breast cancer diagnosed and treated at Aga Khan University Hospital in Nairobi,
Kenya from 2012 to 2018.
PATIENTS AND METHODS We reviewed charts of Kenyan women with metastatic breast cancer and analyzed
sociodemographic data, breast cancer risk factors, and tumor characteristics associated with stage at diagnosis,
receptor status (ie, estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2
[HER2]), and site of metastasis using χ2, analysis of variance, two-sample t tests, and logistic regressions.
RESULTS A total of 125 cases with complete medical records were included in the analysis. Forty women (32%)
hadmetastases at diagnosis. Of the others, those diagnosed in stage III developedmetastases sooner than those
diagnosed in stage II (P , .001). Fifty-eight percent of patients had metastases to bone, 14% to brain, 57% to
lungs, and 50% to liver. Seventy-four percent of patients presented with more than one metastatic site. Me-
tastases to bone were associated with greater age at diagnosis (P = .02) and higher parity (P = .04), and
metastases to the brain were associated with early menopause (P = .04), lower parity (P = .04), and lack of
breastfeeding (P = .01). Patients whose tumors were triple negative (estrogen receptor-negative, progesterone
receptor-negative, and HER2 negative) were more likely to develop brain metastases (P = .01), and those whose
tumors were HER2 positive were more likely to develop liver metastases (P = .04).
CONCLUSION Although our data on patterns of metastases and pathologic subtypes are similar to those in
published literature, some unique findings concerning hormonal risk factors of women with metastatic breast
cancer and specific metastatic sites need additional exploration in larger patient populations.
J Global Oncol. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
In Kenya, the age-standardized rate of breast cancer
incidence is 40.3 per 100,000 women, making it the
most common cancer among Kenyan women.1 In
2013, the reported mortality rate from breast cancer in
Kenya was 7.1 per 100,000 women.2 Corresponding
rates in the United States in 2015 are 124.8 and 20.3
per 100,000 women for incidence and mortality,
respectively.3 In sub-Saharan Africa, the proportion of
patients with breast cancer with late stage (III or IV)
disease at diagnosis ranges from 30% in South Africa
to 98% in Nigeria.4 In Kenya, 42% of women with
breast cancer present in stage III and 18% in stage IV
(metastatic disease).5 In the United States, only 5% to
8% of patients with breast cancer present with stage IV
disease.6
Common sites for breast metastases are the lungs, liver,
bones, and brain.7 The development of metastatic
disease is often unpredictable but has been associated
with the initial stage at diagnosis and with other tumor
characteristics, including receptor status.8 All subtypes
of breast cancer on the basis of hormonal and human
epidermal growth factor receptor 2 (HER2) receptor
status have the potential to become metastatic.7 Other
risk factors for metastases include age, nodal status,
tumor grade, and size.9
Few studies have focused on breast cancer charac-
teristics in African populations; of those published,
most have reported on the molecular profile and
clinical staging of patients with breast cancer.10-13
High-income countries have documented metastatic
disease patterns in relation to receptor status and
molecular subtype of breast cancer.8,14-16 No studies
from sub-Saharan Africa have specifically described
patterns of metastatic breast cancer with patient and
tumor characteristics.
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The purpose of this study was to describe sociodemo-
graphic, clinical, and pathologic characteristics of a series
of Kenyan women with metastatic breast cancer. We an-
alyzed metastatic patterns in this patient population and
identified factors associated with site of metastasis, stage at
initial diagnosis, and receptor status.
PATIENTS AND METHODS
Patients
Patients with metastatic breast cancer from Kenya with
complete medical records who were diagnosed and treated
at Aga Khan University Hospital between January 2012 and
August 2018 were included in this retrospective study. We
analyzed sociodemographic data, breast cancer risk fac-
tors, and tumor characteristics associated with stage at
diagnosis, receptor status (ie, estrogen receptor [ER],
progesterone receptor [PR], and HER2), and site of me-
tastasis. Treatment in the metastatic setting included
chemotherapy with taxane- or nontaxane-based therapy;
radiation at either the breast or metastatic site; hormonal
therapy with tamoxifen, letrozole, or anastrozole; and
trastuzumab-based therapy for those who were HER2
positive.
Hospital Site
Aga Khan University Hospital (AKUH) in Nairobi, Kenya, is
a 250-bed nonprofit institution with a well-established
cancer center. Its Comprehensive Cancer Program pro-
vides care that meets the highest international standards of
practice to patients with cancer throughout East Africa.17
The center provides screening, treatment, palliative care,
and rehabilitation programs. Services include nuclear
medicine, surgery, chemotherapy, radiotherapy, and pa-
thology laboratories.
Ethical Approval
This study was approved by AKUH’s institutional review
board (Ref: 2018/REC-54 [v1]) and all data for analysis
were collected and de-identified by an AKUH research
nurse. Columbia University’s institutional review board
exempted the study from review because study personnel
worked with de-identified data only.
Data Abstraction
AKUH study personnel abstracted all data from electronic
medical records and pathology reports. The data set in-
cluded clinical and demographic information, dates of
diagnosis of primary and metastatic disease, stage at di-
agnosis, site of metastases, and histology of primary tumor
and metastases (including molecular phenotype of primary
tumor on the basis of ER, PR, and HER2 expression).
Sociodemographic and Reproductive Risk Factors
Sociodemographic and reproductive risk factors from chart
review included age at initial breast cancer diagnosis, age at
menarche, age at menopause, menopausal status, parity or
number of childbirths, body mass index, breastfeeding
status, contraception use, family history of cancer, edu-
cational level, smoking history, and alcohol use. All data
including age, body mass index, and menopausal status
were based on the time at original breast cancer diagnosis.
Contraception use was defined as any use of hormonal
contraception, including oral contraceptive pills and long-
acting reversible contraceptives. Family history of cancer
was defined as any first-degree relative diagnosed with any
form of cancer. Educational level was defined by com-
pletion of any accredited primary, secondary, or tertiary
school. Smoking or alcohol use was defined as any patient-
reported use of tobacco cigarettes or standard alcohol
drinks.
Histopathology and Immunohistochemistry
Details of histopathology and immunohistochemistry pro-
cedures at AKUH have been previously described.5 All
biomarker testing was performed at the AKUH pathology
laboratory, which is a College of American Pathologists–
accredited laboratory. Histopathology and prognostic pa-
rameters included stage at diagnosis, tumor size, tumor
type, grade, lymph node positivity, and ER/PR/HER2 sta-
tus. Hormone receptor status was interpreted using the
Allred scoring system, and HER2 status was interpreted
using the ASCO/College of American Pathologists scoring
system.18,19 Molecular subtypes were based on receptor
status alone and organized in the following categories: (1)
ER positive and/or PR positive, and HER2 negative; (2) ER
positive and HER2 positive; (3) ER negative and HER2
positive; and (4) ER negative, PR negative, and HER2
negative (triple negative).
Metastatic Site
Metastases were categorized as bone, brain, lung, and
liver. Patients were evaluated for metastases by x-rays
(lungs/pleura and bone), ultrasound (liver), bone scan
(bone), magnetic resonance imaging (brain), and com-
puted tomography (lung, liver, and brain).
Statistical Analysis
Data were exported to and analyzed using Statistical
Analysis Software (SAS 9.4; SAS Institute, Cary, NC). De-
scriptive statistics were presented as frequencies and
percentages for categorical variables and as means and
standard deviations for continuous variables. Categorical
variables were analyzed using χ2 or Fisher’s exact tests, and
continuous variables were analyzed using t test or analysis
of variance tests to assess the relationships of socio-
demographic risk factors and tumor characteristics with
stage at diagnosis, pathologic subtype, and site of me-
tastasis. Odds ratios (ORs) were calculated using logistic
regressions for significant associations where appropriate.
RESULTS
A total of 1,074 breast cancer cases were diagnosed and
treated at Aga Khan University Hospital during the study
period. One hundred thirty-seven were diagnosed with
Ekpe et al
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TABLE 1. Sociodemographic and Tumor Characteristics by Stage at Initial Diagnosis
Characteristic
Total
(N = 125)
Stage II
(n = 40)
Stage III
(n = 45)
Stage IV
(n = 40) P
Age at diagnosis, years 47.0 6 12 45.8 6 11.1 45.7 6 12.3 46.5 6 12.5 .12
Age at menarche, years 13.1 6 1.5 13.1 6 2.0 12.9 6 1.2 14.1 6 1.9 .06
Age at menopause, years 49.2 6 1.5 49.2 6 1.8 49.1 6 1.4 50.0 6 1.9 .17
Menstrual status .17
Premenopausal 71 (57) 26 (21) 27 (22) 18 (14)
Postmenopausal 54 (43) 14 (11) 18 (14) 22 (18)
Parity (No. of children) 2.9 6 1.8 2.6 6 1.6 3.0 6 1.6 3.0 6 2.1 .20
BMI 27.5 6 4.3 28.0 6 5.3 28.0 6 3.5 26.9 6 5.3 .57
Lactated (breastfed) .13
Yes 113 (90) 33 (26) 43 (34) 37 (30)
No 12 (10) 7 (6) 2 (2) 3 (2)
Used contraception .56
Yes 82 (67) 26 (21) 32 (26) 24 (19)
No 43 (33) 14 (11) 13 (10) 16 (13)
Family history cancer .33
Yes 29 (23) 11 (9) 12 (10) 6 (5)
No 96 (77) 29 (23) 33 (26) 34 (27)
Education level .84
Primary 16 (13) 4 (3) 5 (4) 7 (6)
Secondary 45 (36) 15 (12) 17 (14) 13 (10)
Tertiary 62 (50) 21 (17) 23 (19) 18 (15)
None 2 0 0 2
Ever smoked 1.00
Yes 2 (1.6) 1 (1) 1 (1) 0 (0)
No 123 (98.4) 39 (31) 44 (35) 40 (32)
Ever used alcohol .79
Yes 19 (15) 5 (4) 8 (6) 6 (5)
No 106 (85) 35 (28) 37 (30) 34 (27)
Time from diagnosis to metastasis, months 21.2 6 18.1 30.9 6 22.4 13.0 6 6.6 N/A ,.001
Time from initial symptoms to metastasis, months 20.8 6 18.2 35.4 6 21.9 18.9 6 9.2 8.2 6 9.5 ,.001
Histology type .63
IDC 116 (93) 36 (29) 43 (34) 37 (30)
ILC 9 (7) 4 (3) 2 (2) 3 (2)
Tumor size .004
T1 7 (7) 1 (1) 3 (3) 3 (3)
T2 53 (55) 28 (29) 19 (20) 6 (6)
T3 27 (28) 7 (7) 15 (16) 5 (5)
T4 9 (9) 0 (0) 5 (5) 4 (4)
Unknown 29 4 3 22
Positive lymph nodes 4 6 4 4 6 6 4 6 4 2 6 3 .79
Grade .72
I 4 (3) 1 (1) 2 (2) 1 (1)
II 56 (47) 20 (17) 22 (18) 14 (12)
(Continued on following page)
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metastatic breast cancer, and 125metastatic breast cancer
cases were ultimately included in the study. Those ex-
cluded (n = 12) did not have complete follow-up data. All
patients included in the study were black African women
between the ages of 21 and 79 years. Their mean age at
diagnosis was 47 6 12 years, and their mean age at
menarche was 13.1 6 1.5 years. Among the 54 post-
menopausal patients (43%), the mean age at menopause
was 49.2 6 1.5 years. Eleven patients (19%) were nul-
liparous, and the other 114 averaged three children per
woman; all but one of the mothers breastfed. Sixty-seven
percent of the patients reported ever having used some
form of contraception, and 23% had a family history of
cancer, eight of which were specific for breast cancer. The
majority of patients (99%) had some form of schooling, and
50% had attended university. Only two patients (1.6%) had
a history of smoking cigarettes, and 19 patients (15%)
patients had ever used alcohol (Table 1).
No patients were initially diagnosed at stage I; 40 patients
(32%) were diagnosed at stage II, 45 (36%) at stage III, and
40 (32%) at stage IV (de novo metastases). The majority of
patients had invasive ductal carcinoma (93%), with tumor
grade of 2 (47%) or 3 (50%). Most tumors were ER positive
(70%) and PR positive (58%); 19% of patients had HER2-
positive breast cancer. Sixty percent of patients had
ER-positive and/or PR-positive, HER2-negative molecular
subtype; 12.5% of patients had ER-positive/HER2-positive;
7.5% had ER-negative/HER2-positive; and 20% had triple-
negative tumors. Fifty-eight percent of patients had me-
tastases to bone, 14% to brain, 57% to lungs, and 50% to
liver. Ninety-two patients (74%) developed metastases at
more than one site (Table 1).
Breast Cancer Stage at Diagnosis
A significant association was found between later stage at
diagnosis and shorter duration of time to metastatic dis-
ease: patients diagnosed in stage III developed metastases
sooner than those diagnosed in stage II (OR, 0.89; P ,
.001), averaging at 13.0 months at stage III compared with
30.9 months at stage II. The time between initial symptoms
of breast cancer and metastatic disease was also found to
be significantly associated with stage (OR, 0.88; P, .001);
the average time between initial symptoms of breast cancer
and diagnosis of metastatic disease was 35.4 months for
patients with stage II disease, 18.9 months for stage III, and
8.2 months for stage IV (de novo metastasis). Tumor size
was also associated with stage at initial diagnosis (P = .004;
Table 1).
Breast Cancer Receptor Status/Molecular Subtype
Significant associations were found between PR-positive
status and contraceptive use (OR, 2.83; P = .01) and
between HER2-positive status (irrespective of ER/PR sta-
tus) and younger age at menarche (OR, 0.65; P = .02).
TABLE 1. Sociodemographic and Tumor Characteristics by Stage at Initial Diagnosis (Continued)
Characteristic
Total
(N = 125)
Stage II
(n = 40)
Stage III
(n = 45)
Stage IV
(n = 40) P
III 60 (50) 17 (14) 21 (17) 22 (18)
Unknown 5 0 2 3
Receptor status
ER positive 87 (70) 24 (19) 35 (28) 28 (22) .21
PR positive 73 (58) 22 (18) 27 (22) 24 (19) .87
HER2 positive 23 (19) 7 (6) 9 (8) 7 (6) .93
Molecular subtype
ER positive and/or PR positive, and HER2 negative 72 (60) 22 (18) 27 (22) 23 (19) .89
ER positive/HER2 positive 15 (12.5) 2 (2) 7 (6) 6 (5) .27
ER negative/HER2 positive 9 (7.5) 5 (4) 2 (2) 2 (2) .35
ER negative/PR negative/HER2 negative 24 (20) 9 (7) 7 (6) 8 (7) .70
Metastatic site*
Bone 72 (58) 22 (18) 26 (21) 24 (19) .90
Brain 18 (14) 6 (5) 5 (4) 7 (6) .70
Lung 71 (57) 24 (19) 21 (17) 26 (21) .21
Liver 62 (50) 19 (15) 23 (18) 20 (16) .94
NOTE. Data presented as No. (%) or mean 6 standard deviation.
Abbreviations: BMI, body mass index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; ILC,
invasive lobular carcinoma; N/A , not applicable; PR, progesterone receptor. P values for categorical variables by χ2, continuous variables by t test or analysis
of variance.
*Metastatic site: 92 patients (74%) presented with more than one metastatic site.
Ekpe et al
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TABLE 2. Sociodemographic and Tumor Characteristics of Metastatic Breast Cancer by Receptor Status
Characteristic
ER PR HER2
Positive
(n = 87)
Negative
(n = 38) P
Positive
(n = 73)
Negative
(n = 52) P
Positive
(n = 23)
Negative
(n = 97) P
Age at diagnosis, years 43.5 6 10.9 51.9 6 12.0 .32 42.8 6 11.1 50.8 6 11.3 .19 43.5 6 12.7 46.4 6 11.5 .36
Age at menarche, years 13.2 6 1.4 13.3 6 2.0 .34 13.0 6 1.5 13.5 6 1.8 .17 12.3 6 1.0 13.4 6 1.6 .02
Age at menopause, years 49.2 6 1.5 49.4 6 1.8 .40 49.3 6 1.7 49.2 6 1.5 .82 49.8 6 1.1 49.2 6 1.7 .95
Menstrual status .82 .57 .36
Premenopausal 50 (40) 21 (17) 43 (35) 28 (22) 15 (12) 53 (44)
Postmenopausal 37 (30) 17 (13) 30 (24) 24 (19) 8 (7) 44 (37)
Parity (No. of children) 2.7 6 1.5 3.1 6 2.0 .93 2.7 6 1.5 3.1 6 1.9 .77 2.3 6 1.8 3.0 6 1.6 .82
BMI 27.9 6 4.7 27.9 6 3.6 .64 27.9 6 4.1 27.9 6 5.1 .87 26.0 6 3.2 28.2 6 4.6 .13
Lactated (breastfed) .51 .55 1.00
Yes 80 (64) 33 (26) 67 (53) 46 (37) 21 (17) 88 (73)
No 7 (6) 5 (4.0) 6 (5) 6 (5) 2 (2) 9 (8)
Used contraception .11 .01 .51
Yes 61 (49) 21 (17) 55 (44) 27 (22) 14 (12) 66 (55)
No 26 (20) 17 (14) 18 (14) 25 (20) 9 (7) 31 (26)
Family history cancer .71 .98 .81
Yes 21 (17) 8 (6) 17 (13) 12 (10) 6 (5) 23 (19)
No 66 (53) 30 (24) 56 (45) 40 (32) 17 (14) 74 (62)
Education level .93 .71 1.00
Primary 11 (9) 5 (4) 8 (7) 8 (7) 3 (2) 12 (10)
Secondary 32 (26) 13 (11) 26 (21) 19 (15) 8 (7) 34 (29)
Tertiary 42 (34) 20 (16) 38 (31) 24 (19) 12 (10) 49 (42)
None 2 0 1 1 0 1
Ever smoked .52 1.00 .35
Yes 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1)
No 86 (69) 37 (29) 72 (57) 51 (41) 22 (18) 96 (80)
Ever used alcohol .67 .14 .76
Yes 14 (11) 5 (4) 14 (11) 5 (4) 4 (3) 15 (13)
No 73 (59) 33 (26) 59 (47) 47 (38) 19 (16) 82 (68)
Time from diagnosis to
metastasis, months
19.4 6 14.7 22.7 6 23.6 .66 20.8 6 15.7 19.6 6 20.5 .42 17.7 6 17.9 20.8 6 17.4 .39
Time from symptoms to
metastasis, months
22.8 6 15.3 24.7 6 22.8 .59 24.2 6 15.9 22.0 6 20.3 .87 25.7 6 18.9 22.8 6 17.7 .89
Histology type .72 .73 .65
IDC 80 (64) 36 (29) 67 (54) 49 (39) 21 (17) 91 (76)
ILC 7 (6) 2 (1) 6 (5) 3 (2) 2 (2) 6 (5)
Tumor size .98 .10 .39
T1 5 (5) 2 (2) 5 (5) 2 (2) 0 (0) 7 (8)
T2 38 (40) 15 (16) 34 (35) 19 (20) 9 (10) 43 (47)
T3 19 (20) 8 (8) 15 (16) 12 (13) 7 (8) 18 (19)
T4 6 (6) 3 (3) 2 (2) 7 (7) 2 (2) 6 (6)
Unknown 19 10 17 12 5 23
Positive lymph node 4 6 5 4 6 5 .89 3 6 4 4 6 5 .37 4 6 6 4 6 4 .99
(Continued on following page)
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Receptor status did not seem to be associated with either
stage at diagnosis or tumor grade (Table 2).
Breast Cancer Metastatic Site
Metastasis to bone was associated with greater age at di-
agnosis (OR, 1.04; P = .02) and higher parity (OR, 1.24; P =
.04), whereas metastasis to the brain was associated with
early menopause (OR, 0.45; P = .04), lower parity (OR,
0.71; P = .04), and not breastfeeding (OR, 0.18; P = .01).
However, concerning parity and age at menopause, they
may not be clinically significant given the small differences
in absolute values. Metastasis to the lung was associated
with slightly longer time interval from initial diagnosis to
metastatic disease (OR, 1.03; P = .05). The majority of
patients with bone metastases had ER-positive and PR-
positive cancers; however, these associations were non-
significant. Brain metastases were inversely associated with
ER-positive and PR-positive status (OR, 0.28; P = .01; and
OR, 0.30; P = .02, respectively) and positively associated
with triple-negative tumors (OR, 4.83; P = .01). Both brain
and liver metastases were less common among patients
with ER-positive and/or PR-positive, HER2-negative tumors
(OR, 0.31; P = .02; and OR, 0.43; P = .03, respectively).
However, liver metastases were found to be positively as-
sociated with ER-positive/HER2-positive tumors (OR, 8.02;
P = .002) and HER2-positive status, irrespective of ER or
PR status (OR, 2.75; P = .04; Tables 3 and 4).
DISCUSSION
Our study may be first to describe the metastatic patterns of
a series of Kenyan patients with breast cancer in relation to
demographic and tumor characteristics. Breast cancer can
progress to metastatic disease, or stage IV, regardless of
initial stage at diagnosis. In our study, patients diagnosed in
stage III developed metastases sooner than those di-
agnosed in stage II, and patients who developed lung
metastases had a longer duration of time to metastatic
disease than those who did not develop lung metastases
(irrespective of metastasis to other sites). Although there
are many factors associated with breast carcinoma,
including age at diagnosis, tumor grade and size, lymph
node involvement, and receptor status, it is not always
predictable which tumors will metastasize and to which
site.14 There is a dearth of published literature regarding
initial diagnosis and progression to metastatic disease;
however, among many factors associated with risk of re-
currence for breast cancer, stage at presentation remains
one of the most important.20 Our findings may be a re-
flection of the biology of the tumors. Moreover, tumor size,
which is used to determine stage at initial diagnosis, was
found to be significantly associated with initial stage at
diagnosis, as expected.
Patients diagnosed at later stages and those with negative
hormone and HER2 receptor status were more common
among older patients at diagnosis; however, none of these
associations was significant. In a South African study,
HER2-enriched tumors were more common in younger
patients than were triple-negative tumors.21 In that study, as
in ours, ER and PR status were not strongly associated with
age at diagnosis.21 In our study, patients who developed
metastasis to the bone were significantly associated with
older age at diagnosis. In a literature review of bone me-
tastasis from breast cancer, Pulido et al22 report that some
studies found bone metastases associated with either
younger23 or older age24 at diagnosis, whereas others found
no association at all.25
Hormonal factors are known to play a role in breast cancer
development.26 In our study, PR-positive breast cancer was
associated with contraceptive use (OR, 2.83). Some studies
have suggested that oral contraceptive use may increase
breast cancer risk26; however, Westhoff et al27 report that
long-term use of hormonal contraceptives has not been
found to be associated with overall cancer risk. In our study,
HER2-positive status was found to be associated with early
menarche (OR, 0.65). In contrast, a 2003 study in the
United Kingdom found HER2-positive status to be asso-
ciated with older age at menarche.28 HER2-positive status
is believed to be independent of hormonal risk fac-
tors, including early menarche, late menopause, and
TABLE 2. Sociodemographic and Tumor Characteristics of Metastatic Breast Cancer by Receptor Status (Continued)
Characteristic
ER PR HER2
Positive
(n = 87)
Negative
(n = 38) P
Positive
(n = 73)
Negative
(n = 52) P
Positive
(n = 23)
Negative
(n = 97) P
Grade .32 .20 .73
I 4 (3) 0 (0) 4 (3) 0 (0) 0 (0) 3 (2)
II 40 (34) 16 (13) 33 (28) 23 (19) 9 (8) 46 (40)
III 38 (32) 22 (18) 32 (27) 28 (23) 13 (11) 45 (39)
Unknown 5 0 4 1 1 3
NOTE. Data presented as No. (%) or mean 6 standard deviation. Total of five HER2-equivocal patients without fluorescence in situ hybridization results
were not included in final analysis. P values for categorical variables by χ2, continuous variables by t test or analysis of variance.
Abbreviations: BMI, body mass index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; ILC,
invasive lobular carcinoma; PR, progesterone receptor.
Ekpe et al
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TABLE 3. Sociodemographic and Tumor Characteristics of Metastatic Breast Cancer by Metastatic Site: Bone and Brain
Characteristic
Bone Brain
Yes
(n = 72)
No
(n = 53) P
Yes
(n = 18)
No
(n = 107) P
Age at diagnosis, years 47.8 6 12.6 43.2 6 10.1 .02 49.2 6 13.5 45.3 6 11.5 .31
Age at menarche, years 13.1 6 1.2 13.3 6 2.0 .90 13.2 6 1.6 13.2 6 1.6 .18
Age at menopause, years 49.1 6 1.7 49.7 6 1.2 .52 48.0 6 1.4 49.5 6 1.5 .04
Menstrual status .07 .052
Premenopausal 36 (29) 35 (28) 14 (11) 57 (46)
Postmenopausal 36 (29) 18 (14) 4 (3) 50 (40)
Parity (No. of children) 3.0 6 1.9 2.7 6 1.2 .04 2.1 6 1.8 3.0 6 1.8 .04
BMI 28.0 6 4.5 27.7 6 4.5 .64 28.9 6 4.0 27.7 6 4.5 .96
Lactated (breastfed) .20 .01
Yes 63 (51) 50 (40) 13 (10) 100 (80)
No 9 (7) 3 (2) 5 (4) 7 (6)
Used contraception .11 .33
Yes 43 (35) 39 (31) 10 (8) 72 (58)
No 29 (23) 14 (11) 8 (6) 35 (28)
Family history cancer .47 .56
Yes 15 (12) 14 (11) 3 (2) 26 (21)
No 57 (46) 39 (31) 15 (12) 81 (65)
Education level .17 .53
Primary 12 (10) 4 (3) 1 (1) 15 (12)
Secondary 27 (22) 18 (15) 8 (7) 37 (30)
Tertiary 31 (25) 31 (25) 9 (7) 53 (43)
None 2 0 0 2
Ever smoked 1.00 1.00
Yes 1 (1) 1 (1) 0 (0) 2 (2)
No 71 (57) 52 (41) 18 (14) 105 (84)
Ever used alcohol .63 .30
Yes 10 (8) 9 (7) 1 (1) 18 (14)
No 62 (50) 44 (35) 17 (14) 89 (71)
Time from diagnosis to metastatic
disease, months
19.2 6 14.8 22.1 6 21.2 .38 24.8 6 32.6 19.7 6 14.4 .52
Time from initial symptoms to metastatic
disease, months
22.7 6 14.8 24.3 6 21.0 .32 27.0 6 31.7 22.8 6 14.9 .68
Histology type 1.00 .12
IDC 67 (54) 49 (39) 15 (12) 101 (81)
ILC 5 (4) 4 (3) 3 (2) 6 (5)
Tumor size .83 .55
T1 3 (3) 4 (4) 1 (1) 6 (6)
T2 31 (32) 22 (23) 6 (6) 47 (49)
T3 16 (17) 11 (11) 5 (5) 22 (23)
T4 6 (6) 3 (3) 0 (0) 9 (9)
Unknown 16 13 6 23
Positive lymph nodes 3 6 3 4 6 6 .19 2 6 3 4 6 5 .30
(Continued on following page)
Metastatic Patterns of Breast Cancer, Nairobi, Kenya
Journal of Global Oncology 7
Downloaded from ascopubs.org by 105.27.236.36 on July 14, 2019 from 105.027.236.036
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
nulliparity.28 In addition, our study found that metastasis to
bone was significantly associated with higher parity and
that metastasis to the brain was significantly associated
with early menopause, lower parity, and not breastfeeding.
However, the small differences in absolute values for parity
and age at menopause indicate the results may not be
clinically significant—possibly related to the small sample
size in our study. We have found no other study that has
addressed the relationship between metastatic site and
hormonal risk factors of breast cancer.
The receptor status and molecular subtype distribution in
this series of Kenyan patients with metastatic breast cancer
was similar to that in other studies of patients with breast
cancer (with or without metastases). In a South African
sample, most breast cancers were hormone receptor-
positive, 54% were ER-positive and/or PR-positive, and
HER2-negative tumors; 15% were ER-positive and/or
PR-positive, and HER2-positive tumors; 11% were ER-
negative, PR-negative, and HER2-positive tumors; and
20% were triple-negative tumors.21 Similarly, among our
patients, 60% of breast cancers were ER-positive and/or
PR-positive, and HER2-negative tumors; 12.5% were ER-
positive/HER2-positive tumors; 7.5% ER-negative/HER2-
positive tumors; and 20%were triple negative. Studies have
suggested that breast cancer tends to be more aggressive
and that its molecular subtype is more often triple negative
in African populations than in Western populations.5
However, molecular subtypes vary widely across African
populations, and receptor status in sub-Saharan African is
overall similar to that in the West.5,29 In the South African
study, late-stage and higher-grade tumors were more likely
associated with triple-negative and ER-negative/PR-
negative/HER2-positive tumors than with ER-positive and/
or PR-positive, HER2-negative tumors.21 Triple-negative
and HER2-positive tumors are considered more aggres-
sive than those with positive hormonal receptors.21 In our
sample, however, receptor status was not associated with
either stage at diagnosis or tumor grade.
A number of studies have looked at the relationship be-
tween receptor status and metastatic site.8,14-16 Most
studies reported that bone was the most common site
of breast cancer metastasis. They also found that bone
metastases were associated with ER-positive and/or PR-
positive, HER2-negative and with ER-positive/HER2-
positive tumors; that HER2-positive tumors were strongly
associated with liver metastases; and that triple-negative
tumors were associated with brain metastasis.15,16
Furthermore, brain metastases were more frequent in
ER-negative/PR-negative/HER2-positive tumors than in
ER-positive/PR-positive tumors.14 In our study, bone and
lung metastases were not found to be significantly asso-
ciated with either receptor status or molecular subtype,
although we found significant associations between liver
metastases and HER2-positive status, between liver me-
tastases and ER-positive/HER2-positive tumors, and be-
tween brain metastases and triple-negative tumors. The
TABLE 3. Sociodemographic and Tumor Characteristics of Metastatic Breast Cancer by Metastatic Site: Bone and Brain (Continued)
Characteristic
Bone Brain
Yes
(n = 72)
No
(n = 53) P
Yes
(n = 18)
No
(n = 107) P
Grade .24 .79
I 4 (3) 0 (0) 0 (0) 4 (3)
II 33 (28) 23 (19) 7 (6) 49 (41)
III 33 (28) 27 (22) 10 (8) 50 (42)
Unknown 3 2 1 4
Receptor status
ER positive 53 (42) 34 (27) .26 8 (6) 79 (63) .01
PR positive 41 (33) 32 (26) .70 6 (5) 67 (53) .02
HER2 positive 13 (11) 10 (8) .92 3 (3) 20 (17) 1.00
Molecular subtype
ER positive and/or PR positive,
and HER2 negative
44 (37) 28 (23) .33 6 (5) 66 (55) .02
ER positive/HER2 positive 9 (8) 6 (5) .83 1 (1) 14 (12) .69
ER negative/HER2 positive 5 (4) 4 (3) 1.00 2 (1) 7 (6) .61
ER negative/PR negative/HER2 negative 11 (9) 13 (11) .20 8 (7) 16 (13) .01
NOTE. Data presented as No. (%) or mean 6 standard deviation. P values for categorical variables by χ2, continuous variables by t test or
analysis of variance.
Abbreviations: BMI, body mass index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal
carcinoma; ILC, invasive lobular carcinoma; PR, progesterone receptor.
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TABLE 4. Sociodemographic and Tumor Characteristics by Metastatic Site: Lung and Liver
Characteristic
Lung Liver
Yes
(n = 71)
No
(n = 54) P
Yes
(n = 62)
No
(n = 63) P
Age at diagnosis, years 43.2 6 10.8 49.2 6 12.2 .43 45.7 6 13.5 45.9 6 10.4 .86
Age at menarche, years 13.2 6 1.8 13.2 6 1.2 .97 13.0 6 1.3 13.4 6 1.8 .54
Age at menopause, years 49.3 6 1.6 49.2 6 1.6 .78 49.9 6 1.4 48.8 6 1.6 .37
Menstrual status .18 .78
Premenopausal 44 (34) 27 (22) 36 (29) 35 (28)
Postmenopausal 27 (22) 27 (22) 26 (21) 28 (22)
Parity (No. of children) 2.9 6 1.8 2.8 6 1.5 .39 2.7 6 1.7 2.9 6 1.6 .30
BMI 27.6 6 4.0 28.3 6 4.9 .31 26.7 6 3.4 28.8 6 5.0 .051
Lactated (breastfed) .91 .21
Yes 64 (51) 49 (39) 54 (43) 59 (47)
No 7 (6) 5 (4) 8 (7) 4 (3)
Used contraception .19 .90
Yes 50 (40) 32 (25) 41 (33) 41 (33)
No 21 (17) 22 (18) 21 (17) 22 (17)
Family history cancer .14 .79
Yes 13 (10) 16 (13) 15 (12) 14 (11)
No 58 (47) 38 (30) 47 (38) 49 (39)
Education level .85 .60
Primary 10 (8) 6 (5) 7 (6) 9 (7)
Secondary 26 (21) 19 (15) 21 (17) 24 (19)
Tertiary 34 (28) 28 (23) 34 (28) 28 (23)
None 1 1 0 2
Ever smoked .51 1.00
Yes 2 (2) 0 (0) 1 (1) 1 (1)
No 69 (55) 54 (43) 61 (48) 62 (50)
Ever used alcohol .11 .77
Yes 14 (11) 5 (4) 10 (8) 9 (7)
No 57 (46) 49 (39) 52 (42) 54 (43)
Time from diagnosis to metastatic
disease, months
25.0 6 21.5 15.2 6 9.6 .05 19.9 6 13.3 20.7 6 20.8 .40
Time from initial symptoms to metastatic
disease, months
25.8 6 21.2 20.2 6 10.9 .14 23.9 6 14.6 23.0 6 19.8 .71
Histology type .17 .16
IDC 68 (55) 48 (38) 60 (48) 56 (45)
ILC 3 (2) 6 (5) 2 (1) 7 (6)
Tumor size .83 .14
T1 5 (5) 2 (2) 1 (1) 6 (6)
T2 29 (30) 24 (25) 28 (29) 25 (26)
T3 15 (16) 12 (13) 9 (9) 18 (19)
T4 6 (5) 3 (3) 3 (3) 6 (6)
Unknown 16 13 21 8
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relationship between distant metastatic site and molecular
subtype of breast cancer may be due to homing factors that
target a particular subtype to a specific organ or due to
other undiscovered factors.14
There are a number of limitations in our study, including
small sample size and retrospective study design. All of our
sociodemographic information relied on chart review. In
addition, because not all patients with breast cancer un-
derwent surgery at the time of initial diagnosis, some data
on tumor size, grade, and lymph node positivity were
missing. Furthermore, there were 10 HER2-equivocal
patients, five of whom did not have fluorescence in situ
hybridization results. Those five were not included in the
final HER2 analysis. Finally, 74% of our patients had
metastases to multiple sites, and 26% had involvement of
a single organ. Medical charts reviewed did not differentiate
oligo from multiple metastases for single-organ metastatic
involvement, and breast cancer metastasis to soft tissues
such as the skin were not reported and therefore not
analyzed.
Our study reports sociodemographic, pathologic, and tu-
mor characteristics of a series of African patients with
metastatic breast cancer from a tertiary cancer center in
Nairobi, Kenya. Receptor status and molecular subtype
distributions in this series of patients with metastatic breast
cancer, as well as patterns of metastasis to certain sites in
the body, were overall similar to what has been previously
published. However, some findings concerning hormonal
risk factors of breast cancer and metastatic site are unique
and need additional exploration in larger patient populations.
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